Skip to content

Praxis Precision Medicines

US · PRAX #1645 by market cap Listed 2020
300.43 -10.47 -3.37%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

✦ Quant Ownership Signal how this is computed

Accumulating
  • The number of reporting institutions increased by 34 in the most recent period (2026/Q3).
  • Total institutional ownership rose 3.8 percentage points.

Ownership vs. money flow

Aligned

Institutions added shares last reporting period, and the stock has seen net inflows in main-fund flow over the last 20 trading sessions - the two line up.

Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.

Institutional ownership

Held by institutions
126.86% +3.82pp
Institutions
420 +34
As of
2026/Q3 vs. prior period

Holder types

Mutual Fund82.33%
Hedge Fund23.38%
VC/PE Fund9.44%
Public Company7.10%
Government Pension Fund1.43%
Private Company1.33%
Sovereign Wealth Fund1.25%
Endowment Fund0.30%
Insurance Company0.26%
Individual/Insider0.19%

Top holders as of 2026-06-30

Janus Henderson Group plc 12.24% · 3.42M sh
FMR 9.42% · 2.63M sh
BlackRock 7.99% · 2.23M sh
Perceptive Advisors LLC 7.28% · 2.04M sh
Baker Bros. Advisors LP 6.27% · 1.75M sh
Orbis Investment Management Limited 5.47% · 1.53M sh
Vanguard Portfolio Management, LLC 4.67% · 1.30M sh
Vanguard Capital Management, LLC 4.40% · 1.23M sh
T. Rowe Price Group, Inc. 3.95% · 1.10M sh
State Street Global Advisors 3.74% · 1.04M sh

Bar length is relative to the largest holder shown here, not to 100% of the company.

Insiders

50 filings tracked · 35 buys · 15 sells

NameRoleStake
Dean Mitchell Independent Chairperson 0.06%
Timothy Kelly Chief Financial Officer 0.03%
Alex Nemiroff General Counsel 0.02%
Megan Sniecinski Chief Operating Officer 0.02%
Lauren Mastrocola Former VP of Finance & Principal Accounting Officer 0.01%
Jill DeSimone Independent Director 0.01%
William Young Independent Director 0.01%
Marcio De'Souza Chief Executive Officer 0.00%
Stuart Arbuckle Independent Director 0.00%
Jeffrey Kindler Independent Director 0.00%

Insider transactions most recent Form 4 filings

DateNameRoleTypeSharesPrice
2026-07-07 Marcio De'Souza Chief Executive Officer Other Disposition -23,121 --
2026-06-23 Jill DeSimone Independent Director Derivative Exercise and Sale -11,600 $44.25–315.71
2026-06-09 William Young Independent Director Other Acquisition +1,371 --
2026-06-09 William Young Independent Director Other Derivative Acquisition +648 $240.66
2026-06-09 Jeffrey Kindler Independent Director Other Acquisition +1,371 --
2026-06-09 Jeffrey Kindler Independent Director Other Derivative Acquisition +648 $240.66
2026-06-09 Dean Mitchell Independent Chairperson Other Acquisition +1,371 --
2026-06-09 Dean Mitchell Independent Chairperson Other Derivative Acquisition +648 $240.66
2026-06-09 Gregory Norden Independent Director Other Acquisition +1,371 --
2026-06-09 Gregory Norden Independent Director Other Derivative Acquisition +648 $240.66
2026-06-09 Merit Cudkowicz Independent Director Other Acquisition +1,371 --
2026-06-09 Merit Cudkowicz Independent Director Other Derivative Acquisition +648 $240.66
2026-06-09 Stuart Arbuckle Independent Director Other Acquisition +1,371 --
2026-06-09 Stuart Arbuckle Independent Director Other Derivative Acquisition +648 $240.66
2026-06-09 Jill DeSimone Independent Director Other Acquisition +1,371 --
2026-06-09 Jill DeSimone Independent Director Other Derivative Acquisition +648 $240.66
2026-06-09 Jeffrey Chodakewitz Independent Director Other Acquisition +1,371 --
2026-06-09 Jeffrey Chodakewitz Independent Director Other Derivative Acquisition +648 $240.66
2026-05-13 Alex Nemiroff General Counsel Other Acquisition +78 $167.94
2026-05-13 Marcio De'Souza Chief Executive Officer Other Acquisition +126 $167.94

Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.

Quote time 2026-11-20 20:02:15 · For reference only, not investment advice and not tailored to your situation.

Praxis Precision Medicines discussion 0 comments

Add a comment